Latest Insider Transactions at Cvs Health Corp (CVS)
This section provides a real-time view of insider transactions for Cvs Health Corp (CVS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CVS HEALTH Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CVS HEALTH Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 16
2019
|
Richard J Swift Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,402
+29.79%
|
$124,904
$52.3 P/Share
|
|
May 16
2019
|
Tony L White Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,222
+6.96%
|
$115,544
$52.3 P/Share
|
|
Apr 01
2019
|
Larry J Merlo Director |
SELL
Payment of exercise price or tax liability
|
Direct |
20,858
-5.09%
|
$1,126,332
$54.19 P/Share
|
|
Apr 01
2019
|
Eva C Boratto EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,336
-2.8%
|
$72,144
$54.19 P/Share
|
|
Apr 01
2019
|
Kevin Hourican EVP & President, CVS Pharmacy |
SELL
Payment of exercise price or tax liability
|
Direct |
1,109
-6.78%
|
$59,886
$54.19 P/Share
|
|
Apr 01
2019
|
Thomas M Moriarty EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
4,837
-10.05%
|
$261,198
$54.19 P/Share
|
|
Apr 01
2019
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,606
-4.1%
|
$194,724
$54.19 P/Share
|
|
Apr 01
2019
|
Lisa Bisaccia Former EVP & Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,411
-7.23%
|
$130,194
$54.19 P/Share
|
|
Apr 01
2019
|
Alan Lotvin EVP&President-PharmacyServices |
SELL
Payment of exercise price or tax liability
|
Direct |
863
-10.22%
|
$46,602
$54.19 P/Share
|
|
Apr 01
2019
|
Joshua Matthew Flum EVP, ENT STRATEGY & DIGITAL |
SELL
Payment of exercise price or tax liability
|
Direct |
742
-3.86%
|
$40,068
$54.19 P/Share
|
|
Apr 01
2019
|
James David Clark SVP, Cont & Chief Acct Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
253
-2.69%
|
$13,662
$54.19 P/Share
|
|
Apr 01
2019
|
James David Clark SVP, Cont & Chief Acct Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,536
+28.64%
|
$298,944
$54.19 P/Share
|
|
Mar 11
2019
|
Fernando Aguirre Director |
BUY
Open market or private purchase
|
Direct |
1,900
+10.48%
|
$100,700
$53.59 P/Share
|
|
Mar 11
2019
|
C David Brown Ii Director |
BUY
Open market or private purchase
|
Direct |
10,000
+8.25%
|
$530,000
$53.18 P/Share
|
|
Mar 08
2019
|
David W Dorman Director |
BUY
Open market or private purchase
|
Direct |
9,600
+7.28%
|
$499,200
$52.71 P/Share
|
|
Mar 08
2019
|
Edward J Ludwig Director |
BUY
Open market or private purchase
|
Direct |
2,000
+21.33%
|
$104,000
$52.8 P/Share
|
|
Mar 01
2019
|
Edward J Ludwig Director |
BUY
Open market or private purchase
|
Direct |
4,000
+42.65%
|
$232,000
$58.27 P/Share
|
|
Mar 01
2019
|
Fernando Aguirre Director |
BUY
Open market or private purchase
|
Direct |
3,410
+19.23%
|
$197,780
$58.29 P/Share
|
|
Mar 01
2019
|
James David Clark SVP, Cont & Chief Acct Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,664
+16.28%
|
$74,880
$45.07 P/Share
|
|
Mar 01
2019
|
James David Clark SVP, Cont & Chief Acct Officer |
SELL
Open market or private sale
|
Direct |
1,664
-19.45%
|
$96,512
$58.14 P/Share
|
|
Feb 28
2019
|
Thomas M Moriarty EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
6,120
-15.98%
|
$348,840
$57.83 P/Share
|
|
Feb 28
2019
|
Thomas M Moriarty EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
10,869
+22.1%
|
$619,533
$57.83 P/Share
|
|
Feb 28
2019
|
Eva C Boratto EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
1,893
+4.13%
|
$107,901
$57.83 P/Share
|
|
Feb 28
2019
|
Eva C Boratto EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,101
-2.55%
|
$62,757
$57.83 P/Share
|
|
Feb 28
2019
|
Larry J Merlo Director |
SELL
Payment of exercise price or tax liability
|
Direct |
27,731
-7.63%
|
$1,580,667
$57.83 P/Share
|
|
Feb 28
2019
|
Larry J Merlo Director |
BUY
Grant, award, or other acquisition
|
Direct |
33,431
+8.42%
|
$1,905,567
$57.83 P/Share
|
|
Feb 28
2019
|
James David Clark SVP, Cont & Chief Acct Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,323
+12.71%
|
$75,411
$57.83 P/Share
|
|
Feb 28
2019
|
James David Clark SVP, Cont & Chief Acct Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
288
-3.26%
|
$16,416
$57.83 P/Share
|
|
Feb 28
2019
|
Jonathan C Roberts EVP & Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,183
+11.55%
|
$1,549,431
$57.83 P/Share
|
|
Feb 28
2019
|
Alan Lotvin EVP&President-PharmacyServices |
BUY
Grant, award, or other acquisition
|
Direct |
6,342
+29.52%
|
$361,494
$57.83 P/Share
|
|
Feb 28
2019
|
Alan Lotvin EVP&President-PharmacyServices |
SELL
Payment of exercise price or tax liability
|
Direct |
292
-5.03%
|
$16,644
$57.83 P/Share
|
|
Feb 28
2019
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,114
-5.14%
|
$234,498
$57.83 P/Share
|
|
Feb 28
2019
|
Troyen A Brennan EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,477
+10.6%
|
$540,189
$57.83 P/Share
|
|
Feb 28
2019
|
Joshua Matthew Flum EVP, ENT STRATEGY & DIGITAL |
BUY
Grant, award, or other acquisition
|
Direct |
2,297
+11.45%
|
$130,929
$57.83 P/Share
|
|
Feb 28
2019
|
Joshua Matthew Flum EVP, ENT STRATEGY & DIGITAL |
BUY
Grant, award, or other acquisition
|
Direct |
1,268
+7.25%
|
$72,276
$57.83 P/Share
|
|
Feb 28
2019
|
Joshua Matthew Flum EVP, ENT STRATEGY & DIGITAL |
SELL
Payment of exercise price or tax liability
|
Direct |
990
-6.21%
|
$56,430
$57.83 P/Share
|
|
Feb 28
2019
|
Kevin Hourican EVP & President, CVS Pharmacy |
BUY
Grant, award, or other acquisition
|
Direct |
9,467
+49.19%
|
$539,619
$57.83 P/Share
|
|
Feb 28
2019
|
Kevin Hourican EVP & President, CVS Pharmacy |
SELL
Payment of exercise price or tax liability
|
Direct |
4,489
-93.52%
|
$255,873
$57.83 P/Share
|
|
Feb 28
2019
|
Lisa Bisaccia Former EVP & Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,015
-10.75%
|
$171,855
$57.83 P/Share
|
|
Feb 28
2019
|
Lisa Bisaccia Former EVP & Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,952
+19.87%
|
$396,264
$57.83 P/Share
|
|
Feb 19
2019
|
Karen S Lynch President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
36,617
-23.09%
|
$2,526,573
$69.88 P/Share
|
|
Feb 01
2019
|
Larry J Merlo Director |
SELL
Open market or private sale
|
Direct |
166,368
-33.5%
|
$10,647,552
$64.51 P/Share
|
|
Feb 01
2019
|
Larry J Merlo Director |
BUY
Exercise of conversion of derivative security
|
Direct |
166,368
+25.1%
|
$7,486,560
$45.07 P/Share
|
|
Feb 01
2019
|
Jonathan C Roberts EVP & Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
77,639
-69.69%
|
$4,968,896
$64.54 P/Share
|
|
Feb 01
2019
|
Jonathan C Roberts EVP & Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
77,639
+41.07%
|
$3,493,755
$45.07 P/Share
|
|
Jan 08
2019
|
Larry J Merlo Director |
SELL
Open market or private sale
|
Direct |
166,368
-33.5%
|
$11,479,392
$69.04 P/Share
|
|
Jan 08
2019
|
Larry J Merlo Director |
BUY
Exercise of conversion of derivative security
|
Direct |
166,368
+25.1%
|
$7,486,560
$45.07 P/Share
|
|
Dec 28
2018
|
Mark T Bertolini Director |
SELL
Bona fide gift
|
Direct |
655,982
-98.5%
|
-
|
|
Dec 20
2018
|
Mark T Bertolini Director |
BUY
Other acquisition or disposition
|
Direct |
522,997
+18.99%
|
$35,040,799
$67.26 P/Share
|
|
Dec 20
2018
|
Mark T Bertolini Director |
SELL
Other acquisition or disposition
|
Indirect |
522,997
-100.0%
|
$35,040,799
$67.26 P/Share
|